NSG 554 FNP Exam 3 Prep Document | 2026/2027 Edition |
250 Verified Questions
NSG 554 (Wilkes) Exam 3 2026-2027 Questions and Answers Already Graded A+. 100% Verified Solutions |
Updated Per Latest Guidelines | Graded A+
This comprehensive test bank contains 250 verified exam questions for NSG 554 Exam 3 at Wilkes
University, covering advanced family nurse practitioner (FNP) content. Each question includes correct
answers and rationales, designed to simulate the actual exam experience. The material is updated for
the 2026-2027 academic year, reflecting the latest clinical guidelines and evidence-based practice.
Ideal for focused review and self-assessment to achieve a top score.
Key Features:
250 real exam questions with verified answers
Detailed rationales for correct and incorrect options
Covers all major FNP exam topics: cardiology, pulmonology, endocrinology, etc.
Aligned with 2026-2027 AACN and AANP guidelines
Already graded A+ by previous students
Includes test-taking strategies and clinical pearls
Updates for 2026:
- Updated to reflect 2026-2027 clinical practice guidelines
- Added new questions on COVID-19 management and telehealth
- Revised rationales based on latest evidence-based research
- Enhanced answer explanations with step-by-step clinical reasoning
- Incorporated feedback from recent exam takers
Abstract:
The NSG 554 Exam 3 test bank is a meticulously curated collection of 250 exam-style questions designed to
prepare family nurse practitioner students for their advanced practice examinations. Each question is
accompanied by a correct answer and a comprehensive rationale that explains the underlying pathophysiology,
pharmacology, and clinical reasoning. The content spans core FNP domains including cardiovascular, respiratory,
endocrine, and musculoskeletal systems, with emphasis on differential diagnosis, diagnostic testing, and
management strategies. Updated for the 2026-2027 academic year, this resource aligns with the latest AACN and
AANP competencies and incorporates recent evidence-based guidelines. Students who have utilized this test bank
report improved confidence and higher exam scores, making it an essential tool for achieving a grade of A+ on the
actual exam.
Keywords:
NSG 554 Exam 3, FNP exam prep, Wilkes University, 250 test bank questions, A+ graded answers, 2026-2027
edition, advanced practice nursing, clinical reasoning
Answer Format:
Each question is presented in multiple-choice format with four options. The correct answer is clearly indicated,
followed by a detailed rationale explaining why it is correct and why the other options are incorrect. Rationales
include relevant pathophysiology, pharmacology, and clinical guidelines to reinforce learning.
Compliance Checklist:
Aligned with 2026-2027 AACN FNP competencies
Updated per latest AANP and CDC guidelines
Includes evidence-based rationales for all answers
Page 1
, Covers all major exam content areas
Verified by subject matter experts
Suitable for self-assessment and final review
Content Area Overview:
Content Area Questions Key Topics Weight
Cardiovascular 1-50 hypertension, heart failure, coronary artery 20%
disease, arrhythmias, lipid management
Pulmonary 51-90 asthma, COPD, pneumonia, pulmonary 16%
embolism, sleep apnea
Endocrine 91-130 diabetes mellitus, thyroid disorders, adrenal 16%
insufficiency, metabolic syndrome
Musculoskeletal 131-170 osteoarthritis, rheumatoid arthritis, fractures, 16%
back pain, gout
Neurology 171-210 stroke, headache, dementia, Parkinson's 16%
disease, multiple sclerosis
Miscellaneous 211-250 infectious disease, dermatology, geriatrics, 16%
women's health, mental health
Page 2
,Q1. A patient with type 2 diabetes and stage 3 chronic kidney disease (eGFR 45 mL/min/1.73 m²) is
inadequately controlled on metformin 1000 mg BID and empagliflozin 10 mg daily. HbA1c is 8.9%.
Which of the following medication additions is most appropriate based on current guidelines and
renal function?
A. Liraglutide 0.6 mg subcutaneously daily, titrated to 1.8 mg as tolerated
B. Sitagliptin 100 mg daily
C. Glyburide 5 mg daily initially, with dose adjustments
D. Canagliflozin 300 mg daily
Correct Answer: A. Liraglutide 0.6 mg subcutaneously daily, titrated to 1.8 mg as tolerated
Rationale: Liraglutide is a GLP-1 receptor agonist that is safe in CKD stage 3 and has cardiovascular
benefits. Sitagliptin requires dose adjustment for eGFR <50 (typically 25 mg daily), not 100 mg.
Glyburide carries high risk of hypoglycemia and is best avoided. Canagliflozin is contraindicated when
eGFR is <45 mL/min.
Why Wrong:
B - Sitagliptin dose should be reduced to 25 mg daily in stage 3 CKD; 100 mg is excessive and
increases risk of adverse effects.
C - Glyburide is associated with prolonged hypoglycemia in renal impairment and is not
recommended as a first-line add-on.
D - Canagliflozin is contraindicated when eGFR is below 45 mL/min due to reduced efficacy and
potential for acute kidney injury.
Reference: American Diabetes Association. (2026). Standards of Medical Care in Diabetes-2026.
Diabetes Care, 49(Suppl 1), S1-S266.
Q2. A patient with a history of recurrent major depressive disorder is currently taking fluoxetine 40
mg daily but continues to have significant residual symptoms after 8 weeks. The clinician considers
augmentation. Which of the following augmentation strategies has the strongest evidence for
efficacy in treatment-resistant depression?
A. Adding aripiprazole 2 mg daily
B. Adding buspirone 30 mg daily
C. Switching to venlafaxine 225 mg daily
D. Adding lithium 300 mg BID
Correct Answer: A. Adding aripiprazole 2 mg daily
Rationale: Aripiprazole is FDA-approved as adjunctive therapy for major depressive disorder and has
robust evidence from multiple RCTs. Buspirone has modest evidence, lithium is more established for
bipolar depression but not first-line for unipolar augmentation, and switching to venlafaxine is a strategy
but not augmentation.
Why Wrong:
B - Buspirone has limited data for augmentation in depression and is more commonly used for
anxiety; it is not considered a first-line augmenting agent.
C - Switching agents is a different strategy (not augmentation) and may be appropriate but does not
answer the question about augmentation.
D - Lithium augmentation is effective but is typically reserved for treatment-resistant cases after
other options have failed due to monitoring requirements and side effect burden.
Reference: Trivedi, M.H. et al. (2026). Augmentation strategies for major depressive disorder: A
meta-analysis. JAMA Psychiatry, 83(2), 120-130.
Page 3
, Q3. A patient with moderate persistent asthma is currently using fluticasone/salmeterol 250/50 mcg
one inhalation BID and reports using albuterol 3-4 times per week. According to the 2026 GINA
guidelines, what is the recommended step-up approach?
A. Increase fluticasone/salmeterol to 500/50 mcg BID
B. Add tiotropium 2.5 mcg two inhalations once daily
C. Switch to fluticasone furoate/vilanterol 200/25 mcg once daily
D. Add montelukast 10 mg daily
Correct Answer: B. Add tiotropium 2.5 mcg two inhalations once daily
Rationale: For patients on medium-dose ICS/LABA with poor control, GINA 2026 recommends adding
tiotropium as the preferred step-up. Increasing to high-dose ICS/LABA is an alternative but not first-line.
Switching to a different ICS/LABA is not recommended without prior optimization. Adding montelukast is
less effective than tiotropium at this step.
Why Wrong:
A - High-dose ICS/LABA is an option but is no longer preferred due to increased side effects;
tiotropium is recommended first.
C - Switching to another ICS/LABA without increasing dose does not address inadequate control
and is not supported by guidelines.
D - Montelukast is less potent than tiotropium as add-on therapy and is not the preferred step-up at
this level.
Reference: Global Initiative for Asthma. (2026). Global Strategy for Asthma Management and
Prevention. GINA.
Q4. A patient with a BMI of 34 kg/m² and prediabetes (HbA1c 6.2%) is interested in
pharmacotherapy for weight loss. Which of the following medications is most appropriate as
first-line for both weight management and prevention of diabetes progression?
A. Liraglutide 3.0 mg daily
B. Orlistat 120 mg TID
C. Metformin 500 mg BID
D. Phentermine/topiramate ER 7.5/46 mg daily
Correct Answer: A. Liraglutide 3.0 mg daily
Rationale: Liraglutide 3.0 mg is FDA-approved for chronic weight management and has demonstrated
efficacy in preventing progression to type 2 diabetes in prediabetes. Orlistat is less effective and not
preferred for diabetes prevention. Metformin is not FDA-approved for weight loss, though it may prevent
diabetes. Phentermine/topiramate is effective but not first-line for prediabetes due to teratogenicity and
monitoring requirements.
Why Wrong:
B - Orlistat has modest weight loss and no proven benefit in diabetes prevention; it also has
gastrointestinal side effects that limit adherence.
C - Metformin is not approved for weight loss and its effect on weight is modest; it is used for
diabetes prevention but not as a primary weight loss agent.
D - Phentermine/topiramate is effective but requires careful monitoring and is not the first choice in
prediabetes due to potential fetal harm and need for contraception.
Reference: American Diabetes Association. (2026). Prevention or delay of type 2 diabetes: Standards of
Care. Diabetes Care, 49(Suppl 1), S40-S45.
Page 4
250 Verified Questions
NSG 554 (Wilkes) Exam 3 2026-2027 Questions and Answers Already Graded A+. 100% Verified Solutions |
Updated Per Latest Guidelines | Graded A+
This comprehensive test bank contains 250 verified exam questions for NSG 554 Exam 3 at Wilkes
University, covering advanced family nurse practitioner (FNP) content. Each question includes correct
answers and rationales, designed to simulate the actual exam experience. The material is updated for
the 2026-2027 academic year, reflecting the latest clinical guidelines and evidence-based practice.
Ideal for focused review and self-assessment to achieve a top score.
Key Features:
250 real exam questions with verified answers
Detailed rationales for correct and incorrect options
Covers all major FNP exam topics: cardiology, pulmonology, endocrinology, etc.
Aligned with 2026-2027 AACN and AANP guidelines
Already graded A+ by previous students
Includes test-taking strategies and clinical pearls
Updates for 2026:
- Updated to reflect 2026-2027 clinical practice guidelines
- Added new questions on COVID-19 management and telehealth
- Revised rationales based on latest evidence-based research
- Enhanced answer explanations with step-by-step clinical reasoning
- Incorporated feedback from recent exam takers
Abstract:
The NSG 554 Exam 3 test bank is a meticulously curated collection of 250 exam-style questions designed to
prepare family nurse practitioner students for their advanced practice examinations. Each question is
accompanied by a correct answer and a comprehensive rationale that explains the underlying pathophysiology,
pharmacology, and clinical reasoning. The content spans core FNP domains including cardiovascular, respiratory,
endocrine, and musculoskeletal systems, with emphasis on differential diagnosis, diagnostic testing, and
management strategies. Updated for the 2026-2027 academic year, this resource aligns with the latest AACN and
AANP competencies and incorporates recent evidence-based guidelines. Students who have utilized this test bank
report improved confidence and higher exam scores, making it an essential tool for achieving a grade of A+ on the
actual exam.
Keywords:
NSG 554 Exam 3, FNP exam prep, Wilkes University, 250 test bank questions, A+ graded answers, 2026-2027
edition, advanced practice nursing, clinical reasoning
Answer Format:
Each question is presented in multiple-choice format with four options. The correct answer is clearly indicated,
followed by a detailed rationale explaining why it is correct and why the other options are incorrect. Rationales
include relevant pathophysiology, pharmacology, and clinical guidelines to reinforce learning.
Compliance Checklist:
Aligned with 2026-2027 AACN FNP competencies
Updated per latest AANP and CDC guidelines
Includes evidence-based rationales for all answers
Page 1
, Covers all major exam content areas
Verified by subject matter experts
Suitable for self-assessment and final review
Content Area Overview:
Content Area Questions Key Topics Weight
Cardiovascular 1-50 hypertension, heart failure, coronary artery 20%
disease, arrhythmias, lipid management
Pulmonary 51-90 asthma, COPD, pneumonia, pulmonary 16%
embolism, sleep apnea
Endocrine 91-130 diabetes mellitus, thyroid disorders, adrenal 16%
insufficiency, metabolic syndrome
Musculoskeletal 131-170 osteoarthritis, rheumatoid arthritis, fractures, 16%
back pain, gout
Neurology 171-210 stroke, headache, dementia, Parkinson's 16%
disease, multiple sclerosis
Miscellaneous 211-250 infectious disease, dermatology, geriatrics, 16%
women's health, mental health
Page 2
,Q1. A patient with type 2 diabetes and stage 3 chronic kidney disease (eGFR 45 mL/min/1.73 m²) is
inadequately controlled on metformin 1000 mg BID and empagliflozin 10 mg daily. HbA1c is 8.9%.
Which of the following medication additions is most appropriate based on current guidelines and
renal function?
A. Liraglutide 0.6 mg subcutaneously daily, titrated to 1.8 mg as tolerated
B. Sitagliptin 100 mg daily
C. Glyburide 5 mg daily initially, with dose adjustments
D. Canagliflozin 300 mg daily
Correct Answer: A. Liraglutide 0.6 mg subcutaneously daily, titrated to 1.8 mg as tolerated
Rationale: Liraglutide is a GLP-1 receptor agonist that is safe in CKD stage 3 and has cardiovascular
benefits. Sitagliptin requires dose adjustment for eGFR <50 (typically 25 mg daily), not 100 mg.
Glyburide carries high risk of hypoglycemia and is best avoided. Canagliflozin is contraindicated when
eGFR is <45 mL/min.
Why Wrong:
B - Sitagliptin dose should be reduced to 25 mg daily in stage 3 CKD; 100 mg is excessive and
increases risk of adverse effects.
C - Glyburide is associated with prolonged hypoglycemia in renal impairment and is not
recommended as a first-line add-on.
D - Canagliflozin is contraindicated when eGFR is below 45 mL/min due to reduced efficacy and
potential for acute kidney injury.
Reference: American Diabetes Association. (2026). Standards of Medical Care in Diabetes-2026.
Diabetes Care, 49(Suppl 1), S1-S266.
Q2. A patient with a history of recurrent major depressive disorder is currently taking fluoxetine 40
mg daily but continues to have significant residual symptoms after 8 weeks. The clinician considers
augmentation. Which of the following augmentation strategies has the strongest evidence for
efficacy in treatment-resistant depression?
A. Adding aripiprazole 2 mg daily
B. Adding buspirone 30 mg daily
C. Switching to venlafaxine 225 mg daily
D. Adding lithium 300 mg BID
Correct Answer: A. Adding aripiprazole 2 mg daily
Rationale: Aripiprazole is FDA-approved as adjunctive therapy for major depressive disorder and has
robust evidence from multiple RCTs. Buspirone has modest evidence, lithium is more established for
bipolar depression but not first-line for unipolar augmentation, and switching to venlafaxine is a strategy
but not augmentation.
Why Wrong:
B - Buspirone has limited data for augmentation in depression and is more commonly used for
anxiety; it is not considered a first-line augmenting agent.
C - Switching agents is a different strategy (not augmentation) and may be appropriate but does not
answer the question about augmentation.
D - Lithium augmentation is effective but is typically reserved for treatment-resistant cases after
other options have failed due to monitoring requirements and side effect burden.
Reference: Trivedi, M.H. et al. (2026). Augmentation strategies for major depressive disorder: A
meta-analysis. JAMA Psychiatry, 83(2), 120-130.
Page 3
, Q3. A patient with moderate persistent asthma is currently using fluticasone/salmeterol 250/50 mcg
one inhalation BID and reports using albuterol 3-4 times per week. According to the 2026 GINA
guidelines, what is the recommended step-up approach?
A. Increase fluticasone/salmeterol to 500/50 mcg BID
B. Add tiotropium 2.5 mcg two inhalations once daily
C. Switch to fluticasone furoate/vilanterol 200/25 mcg once daily
D. Add montelukast 10 mg daily
Correct Answer: B. Add tiotropium 2.5 mcg two inhalations once daily
Rationale: For patients on medium-dose ICS/LABA with poor control, GINA 2026 recommends adding
tiotropium as the preferred step-up. Increasing to high-dose ICS/LABA is an alternative but not first-line.
Switching to a different ICS/LABA is not recommended without prior optimization. Adding montelukast is
less effective than tiotropium at this step.
Why Wrong:
A - High-dose ICS/LABA is an option but is no longer preferred due to increased side effects;
tiotropium is recommended first.
C - Switching to another ICS/LABA without increasing dose does not address inadequate control
and is not supported by guidelines.
D - Montelukast is less potent than tiotropium as add-on therapy and is not the preferred step-up at
this level.
Reference: Global Initiative for Asthma. (2026). Global Strategy for Asthma Management and
Prevention. GINA.
Q4. A patient with a BMI of 34 kg/m² and prediabetes (HbA1c 6.2%) is interested in
pharmacotherapy for weight loss. Which of the following medications is most appropriate as
first-line for both weight management and prevention of diabetes progression?
A. Liraglutide 3.0 mg daily
B. Orlistat 120 mg TID
C. Metformin 500 mg BID
D. Phentermine/topiramate ER 7.5/46 mg daily
Correct Answer: A. Liraglutide 3.0 mg daily
Rationale: Liraglutide 3.0 mg is FDA-approved for chronic weight management and has demonstrated
efficacy in preventing progression to type 2 diabetes in prediabetes. Orlistat is less effective and not
preferred for diabetes prevention. Metformin is not FDA-approved for weight loss, though it may prevent
diabetes. Phentermine/topiramate is effective but not first-line for prediabetes due to teratogenicity and
monitoring requirements.
Why Wrong:
B - Orlistat has modest weight loss and no proven benefit in diabetes prevention; it also has
gastrointestinal side effects that limit adherence.
C - Metformin is not approved for weight loss and its effect on weight is modest; it is used for
diabetes prevention but not as a primary weight loss agent.
D - Phentermine/topiramate is effective but requires careful monitoring and is not the first choice in
prediabetes due to potential fetal harm and need for contraception.
Reference: American Diabetes Association. (2026). Prevention or delay of type 2 diabetes: Standards of
Care. Diabetes Care, 49(Suppl 1), S40-S45.
Page 4
